Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 8, Issue 2, Pages e001185
Publisher
BMJ
Online
2020-09-19
DOI
10.1136/jitc-2020-001185
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- γδ T cells bring unconventional cancer-targeting to the clinic — again
- (2020) Ken Garber NATURE BIOTECHNOLOGY
- γ9δ2T cell diversity and the receptor interface with tumor cells
- (2020) Anna Vyborova et al. JOURNAL OF CLINICAL INVESTIGATION
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma
- (2019) Mohammed Alnaggar et al. Journal for ImmunoTherapy of Cancer
- Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies
- (2019) Zsolt Sebestyen et al. NATURE REVIEWS DRUG DISCOVERY
- Unconventional T Cell Targets for Cancer Immunotherapy
- (2018) Dale I. Godfrey et al. IMMUNITY
- Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation
- (2018) Anna Capsomidis et al. MOLECULAR THERAPY
- Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy
- (2018) Jonathan Fisher et al. Frontiers in Immunology
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- CD27 - CD45 + γδ T cells can be divided into two populations, CD27 - CD45 int and CD27 - CD45 hi with little proliferation potential
- (2016) Kosuke Odaira et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- A new high-throughput sequencing method for determining diversity and similarity of T cell receptor (TCR) α and β repertoires and identifying potential new invariant TCR α chains
- (2016) Kazutaka Kitaura et al. BMC IMMUNOLOGY
- Heterogeneous yet stable Vδ2(+)T-cell profiles define distinct cytotoxic effector potentials in healthy human individuals
- (2016) Paul L. Ryan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell Receptor
- (2016) Zsolt Sebestyen et al. Cell Reports
- Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2015) Gregory A. Masters et al. JOURNAL OF CLINICAL ONCOLOGY
- γδT Cells: First Line of Defense and Beyond
- (2014) Yueh-hsiu Chien et al. Annual Review of Immunology
- The Intracellular B30.2 Domain of Butyrophilin 3A1 Binds Phosphoantigens to Mediate Activation of Human Vγ9Vδ2 T Cells
- (2014) Andrew Sandstrom et al. IMMUNITY
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
- (2014) Edward B Garon et al. LANCET
- Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer
- (2014) Ikuo Wada et al. Cancer Medicine
- Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain
- (2013) Takamichi Izumi et al. CYTOTHERAPY
- 9 and 2CDR3 domains regulate functional avidity of T cells harboring 9 2TCRs
- (2012) C. Grunder et al. BLOOD
- Adoptive Immunotherapy for Advanced Non-small CellLung Cancer Using Zoledronate-expanded γδTCells
- (2011) Miki Sakamoto et al. JOURNAL OF IMMUNOTHERAPY
- Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
- (2011) Makoto Kondo et al. Jove-Journal of Visualized Experiments
- The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to T-cell cytotoxicity
- (2010) T. Lanca et al. BLOOD
- Impact of culture medium on the expansion of T cells for immunotherapy
- (2009) Keisuke Sato et al. CYTOTHERAPY
- The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies
- (2009) G. Scagliotti et al. ONCOLOGIST
- Zoledronate facilitates large-scale ex vivo expansion of functional γδ T cells from cancer patients for use in adoptive immunotherapy*
- (2008) M. Kondo et al. CYTOTHERAPY
- Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer
- (2008) Riichiroh Maruyama et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started